P-glycoprotein and human immunodeficiency virus infection;Glucoproteína P e infección por el virus de la inmunodeficiencia humana

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 3, 2008, Pages 150-159

  Peralta, Galo ^a   Sánchez, María Blanca ^b   Echevarría, Santiago ^b   Valdizán, Elsa María ^b   Armijo, Juan Antonio ^b  

^a HOSPITAL SIERRALLANA   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiretroviral therapy; HIV; MDR 1 gene; P glycoprotein; Pharmacogenetics; Polymorphisms

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; GLYCOPROTEIN P; INDINAVIR; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; OC 144 093; ONT 093; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG; VALSPODAR; ZALCITABINE; ZIDOVUDINE; ZOSUQUIDAR;

DRUG BLOOD LEVEL; DRUG EFFICACY; EXON; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 40949113564     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13116752     Document Type: Review

References (107)

1. Lowe SH, Prins JM, Lange JM. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. Neth J Med. 2004;62:424-40.
2. Deeks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clin Infect Dis. 2000;30 Suppl 2: S177-84.
3. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185 Suppl 2: S143-51.
4. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31:S112-7.
5. Quirk E, McLeod H, Powderly W. The pharmacogenetics of antiretroviral therapy: a review of studies to date. Clin Infect Dis. 2004;39:98-106.
6. Rodríguez-Novoa S, Barreiro P, Jiménez-Nacher I, Soriano V. Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J. 2006;6:234-45.
7. Roots I, Gerloff T, Meisel C, Kirchheiner J, Goldammer M, Kaiser R, et al. Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev. 2004;36:617-38.
8. Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem. 2004;4:1399-409.
9. Allorge D, Loriot MA. Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport. Ann Biol Clin (Paris). 2004;62:499-511.
10. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphism inhuman MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
11. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161-70.
12. Van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 1996;87:507-17.
13. Schinkel A, Mayer U, Wagenaar E, Mol C, Van Deemter L, Smit J, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997;94:4028-33.
14. Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-8.
15. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-94.
16. Izzedine H, Launay-Vacher V, Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS. 2005;19:455-62.
17. Smit JW, Schinkel AH, Muller M, Weert B, Meijer DK. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology. 1998;27:1056-63.
18. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampicin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-92.
19. Drewe J, Gutmann H, Fricker G, Torok M, Berlinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57:1147-52.
20. Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004;26:322-30.
21. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS. 2001;15:1353-8.
22. Jones K, Hoggard PG, Sales SD, Khoo, Davey R, Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS. 2001;15:675-81.
23. Choo EF, Leake B, Wandel C, Inamura H, Wood AJ, Wilkinson Gr, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655-60.
24. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Bejinen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59:806-13.
25. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, et al. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos. 2000;28:1058-62.
26. Smit JW, Huisman MT, Van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest. 1999;104:1441-7.
27. Van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS. 2000;14:1187-94.
28. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res. 2005;11:7764-72.
29. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-7.
30. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-22.
31. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol. 2003;77:7383-92.
32. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among Europeans Americans and African Americans. Clin Pharmacol Ther. 2001;70:189-99.
33. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multi-drug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001;297:1137-43.
34. Brinkmann U. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P-glycoprotein expresion and activity in vivo. Novartis Found Symp. 2002;243:207-10.
35. Gervasini G, Vizcaíno S, Gasiba C, Carrillo JA, Benítez J. Differences in CYP3A5*3 Genotype Distribution and Combinations With Other Polymorphisms Between Spaniards and Other Caucasian Populations. Ther Drug Monit. 2005;27:819-21.
36. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med. 2003;348:1442-8.
37. Zheng H, Webber S, Zeevi A, Schetz E, Zhang J, Lamba J, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol. 2002;63:765-70.
38. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-6.
39. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS. 2003;17:201-8.
40. Turriziani O, Antonelli G, Dianzani F. Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. Int J Antimicrob Agents. 2000;16:353-6.
41. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesman MM. Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter. FASEB J. 2000;14:516-22.
42. Speck RR, Yu XF, Hildreth J, Flexner C. Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis. 2002;186:332-40.
43. Raviv Y, Puri A, Blumenthal R. P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane. FASEB J. 2000;14:511-5.
44. Bleiber G, May M, Suárez C, Martínez R, Marzolini C, Egger M, et al. MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment. J Infect Dis. 2004;189:583-6.
45. Owen A, Chandler B, Bray PG, Ward SA, Hart CA, Back DJ, et al. Functional correlation of P-glycoprotein expression and genotype with expression of the human immunodeficiency virus type 1 coreceptor CXCR4. J Virol. 2004;78:12022-9.
46. Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J. 2000;17:253-9.
47. Ifergan I, Bernard NF, Bruneau J, Alary M, Tsoukas CM, Roger M. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS. 2002;16:2340-2.
48. Gollapudi S, Gupta S. Human immunodeficiency virus I - induced expression of P-glycoprotein. Biochem Biophys Res Común. 1990;171:1002-7.
49. Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem. 2005;93:1231-41.
50. Jorajuria S, Clayette P, Dereuddre-Bosquet N, Benlhassan-Chahour K, Thiebot H, Vaslin B, et al. The expression of P-glycoprotein and cellular kinases is modulated at the transcriptional level by infection and highly active antiretroviral therapy in a primate model of AIDS. AIDS Res Hum Retroviruses. 2003;19:307-11.
51. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, Gupta S. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses. 1996;12:1457-62.
52. Lucia MB, Cauda R, Landay AL, Malorni W, Donelli G, Ortona L. Transmembrane P-glycoprotein (PGP/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res Hum Retroviruses. 1995;11:893-901.
53. Meaden ER, Hoggard PG, Maher B, Khoo SH, Back DJ. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses. 2001;17:1329-32.
54. Malorni W, Lucia MB, Rainaldi G, Cauda R, Cianfriglia M, Donelli G, et al. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. Haematologica. 1998;83:13-20.
55. Lucia MB, Rutella S, Rumi C, Ventura G, Caldarola G, Cauda R. Detection of P-glycoprotein efflux activity on peripheral blood lymphocyte subsets from HIV + patients. Eur J Histochem. 1997;41 Suppl 2:195-6.
56. Lucia MB, Rutella S, Rumi C, Cauda R. Surface P-glycoprotein expression on peripheral lymphocyte subpopulations from HIV-infected patients. Eur J Histochem. 1997;41 Suppl 2:33-4.
57. Bossi P, Legrand O, Faussat AM, Legrand M, Bricaire F, Marie JP, et al. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors. HIV Med. 2003;4:67-71.
58. Lucia MB, Rutella S, Leone G, Larocca LM, Vella S, Cauda R. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin. J Acquir Immune Defic Syndr. 2002;30:369-78.
59. Stormer E, Von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by nonnucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res. 2002;19:1038-45.
60. Haas DW, Bartlett J, Anderson J, Sanne I, Wilkinson GR, Quinn J, et al. Pharmacogenetics of nevirapine and hepatoxicity: NWCS220, an ACTG collaborative study. In: Proceedings of the Twelfth Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, Massachusetts. Abstract 833.
61. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, et al. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr. 2003;15;33:551-6.
62. Gutman H, Fricker G, Drewe J, Toeroek M, Miller DS. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol. 1999;56:383-9.
63. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (PGP) in human cultured cells. J Acquir Immune Defic Syndr. 1998;19:203-9.
64. Perloff MD, Von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000;14:1287-9.
65. Lucia MB, Rutella S, Leone G, Vella S, Cauda R. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr. 2001;27:321-30.
66. Donahue JP, Dowdy D, Ratnam KK, Hulgan T, Price J, Unutmaz D, et al. Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy. Clin Pharmacol Ther. 2003;73:78-86.
67. Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS. 1999;13:1623-7.
68. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharm Bull. 2000;23:1528-31.
69. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005;39:635-7.
70. Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, Von Moltke LL. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005;33:764-70.
71. Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, et al. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS. 2005;19:371-80.
72. Berruet N, Sentenac S, Auchere D, Giménez F, Farinotti R, Fernández C. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci. 2005;8:226-34.
73. Hulgan T, Donahue JP, Hawkins C, Unutmaz D, D'Aquila RT, Raffanti S, et al. Implications of T-cell P-glycoprotein activity during HIV-1 infection and its therapy. J Acquir Immune Defic Syndr. 2003;34:119-26.
74. Owen A, Almond L, Hartkoorn R, Walsh T, Youle M, Bonington A, et al. Relevance of drug transporters and drug metabolism enzymes to nevirapine disposition: superimposition of host genotypes. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachusetts. Abstract 650.
75. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H, et al. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res. 2003;8:531-4.
76. Verstuyft C, Marcellin F, Morand-Joubert L, Launay O, Brendel K, Mentre F, et al. Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. AIDS. 2005;19:2127-31.
77. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, et al. Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005;192:1931-42.
78. Antonelli G, Turriziani O, Cianfriglia M, Riva E, Dong G, Fattorossi A, et al. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res Hum Retroviruses. 1992;8:1839-44.
79. Hoggard PG, Back DJ. Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules. Curr Opin Infect Dis. 2002;15:3-8.
80. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, PGP and BCRP. AIDS. 2005;19:2097-102.
81. Chaillou S, Durant J, Garraffo R, Georgenthum E, Roptin C, Dunais B, et al. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials. 2002;3:493-501.
82. Hennessy M, Clarke S, Spiers JP, Kelleher D, Mulcahy F, Hoggard P, et al. Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients. Antivir Ther. 2004;9:115-22.
83. Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, et al. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2388-93.
84. Almond LM, Hoggard PG, Edirisinghe D, Khoo SH, Back DJ. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 2005;56:738-44.
85. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005;78:132-42.
86. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, et al. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr. 2003;34:295-8.
87. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, et al. MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS. 2003;17:1696-8.
88. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5.
89. Gutiérrez F, Navarro A, Padilla S, Antón R, Masía M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
90. Haas DW, RiBbaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400.
91. Ritchie M, Haas D, Motsinger A, Donahue J, Erdem H, Raffanti S, et al. Genetic variation in drug transporter and metabolizing enzyme genes may be associated with non-nucleoside reverse transcriptase inhibitor hepatotoxicity. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Massachussets. Abstract 832.
92. Cooper CL, Van Heeswijk RP, Gallicano K, Cameron DW. A review of lowdose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36:1585-92.
93. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998;16:2964-76.
94. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res. 2004;10:4724-33.
95. Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, et al. Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer. 2005;93:46-53.
96. Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, Leggas M. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metab Dispos. 2006;34:653-9.
97. Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res. 2004;10:3265-72.
98. Chi KN, Chia SK, Dixon R, Newman MJ, Wacher VJ, Sikic B, et al. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005;23:311-5.
99. Kuppens IE, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol. 2005;55:72-8.
100. Mistry P, Folkes A. ONT-093 (Ontogen). Curr Opin Investig Drugs. 2002;3:1666-71.
101. Ramachandran C, Wellham LL. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res. 2003;23:2681-90.
102. Kang H, Fisher MH, Xu D, Miyamoto YJ, Marchand A, Van Aerschot A, et al. Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides. Nucleic Acids Res. 2004;32:4411-9.
103. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol. 2004;66:268-75.
104. Xu D, Ye D, Fisher M, Juliano RL. Selective inhibition of P-glycoprotein expression in multidrug-resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther. 2002;302:963-71.
105. Matsushita H, Kizaki M, Kobayashi H, Ueno H, Muto A, Takayama N, et al. Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells. Blood. 1998;91:2452-8.
106. Kobayashi H, Dorai T, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 1994;54:1271-5.
107. Wang FS, Kobayashi H, Liang KW, Holland JF, Ohnuma T. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther. 1999;10:1185-95.